Destiny Pharma has joined a growing list of UK biotechs seeking to delist from the Alternative Investments Market (AIM) and return to private ownership.
The US government has signed a $176 million deal with Moderna to develop an mRNA-based pandemic influenza vaccine, as reports emerge of a fifth human case of H5N1 flu linked to ongoing outb
The non-profit International Society for Infectious Diseases (ISID) has published a set of six priorities focusing on the challenges faced by low- and middle-income countries (LMICs) ahead
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults.
CSL Seqirus has agreed to provide 665,000 doses of a bird flu vaccine to the European Commission as part of the EU’s efforts to prepare for a potential outbreak of the disease, with a
Moderna says it has become the first company in the pharma sector with phase 3 data on a combined vaccine for both COVID-19 and influenza and will soon be ready to discuss